Literature DB >> 20097731

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.

Zhenfeng Zhang1, Susumu Kobayashi, Alain C Borczuk, Rom S Leidner, Thomas Laframboise, Alan D Levine, Balazs Halmos.   

Abstract

Mitogen-activated protein kinase (MAPK) pathway signaling plays an important role in the majority of non-small-cell lung cancers (NSCLCs). In a prior microarray analysis of epidermal growth factor receptor (EGFR) inhibition in NSCLC cell lines, we noted that several dual specificity phosphatases (DUSPs) were among the most highly and immediately regulated genes. DUSPs act as natural terminators of MAPK signal transduction and therefore, we hypothesized a tumor suppressive role via feedback mechanisms. In the current study, we focus on the assessment of DUSP6, a cytoplasmic DUSP with high specificity for extracellular signal-regulated kinase (ERK). We demonstrate that DUSP6 expression tracks in tandem with ERK inhibition and that regulation of DUSP6 is mediated at the promoter level by ETS1, a well-known nuclear target of activated ERK. Small interfering RNA knockdown in DUSP6-high H441 lung cancer cells significantly increased ERK activation and cellular proliferation, whereas plasmid-driven overexpression in DUSP6-low H1975 lung cancer cells significantly reduced ERK activation and cellular proliferation and promoted apoptosis. Also, DUSP6 overexpression synergized with EGFR inhibitor treatment in EGFR-mutant HCC827 cells. Our results indicate that DUSP6 expression is regulated by ERK signaling and that DUSP6 exerts antitumor effects via negative feedback regulation, pointing to an important feedback loop in NSCLC. Further studies assessing the tumor suppressive role of DUSP6 and strategies aimed at modulation of its activity are warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20097731      PMCID: PMC2847094          DOI: 10.1093/carcin/bgq020

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.741


  47 in total

Review 1.  Structure and regulation of MAPK phosphatases.

Authors:  Amjad Farooq; Ming-Ming Zhou
Journal:  Cell Signal       Date:  2004-07       Impact factor: 4.315

2.  MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase.

Authors:  M Muda; U Boschert; R Dickinson; J C Martinou; I Martinou; M Camps; W Schlegel; S Arkinstall
Journal:  J Biol Chem       Date:  1996-02-23       Impact factor: 5.157

3.  The noncatalytic amino terminus of mitogen-activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation.

Authors:  J Julie Wu; Lei Zhang; Anton M Bennett
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

4.  The mitogen-activated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificity.

Authors:  M Muda; A Theodosiou; C Gillieron; A Smith; C Chabert; M Camps; U Boschert; N Rodrigues; K Davies; A Ashworth; S Arkinstall
Journal:  J Biol Chem       Date:  1998-04-10       Impact factor: 5.157

5.  Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.

Authors:  Koji Okudela; Takuya Yazawa; Tetsukan Woo; Masashi Sakaeda; Jun Ishii; Hideaki Mitsui; Hiroaki Shimoyamada; Hanako Sato; Michihiko Tajiri; Nobuo Ogawa; Munetaka Masuda; Takashi Takahashi; Haruhiko Sugimura; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

6.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

7.  Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.

Authors:  David W Chan; Vincent W S Liu; George S W Tsao; Kwok-Ming Yao; Toru Furukawa; Karen K L Chan; Hextan Y S Ngan
Journal:  Carcinogenesis       Date:  2008-07-16       Impact factor: 4.944

8.  Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras.

Authors:  Janel K Warmka; Laura J Mauro; Elizabeth V Wattenberg
Journal:  J Biol Chem       Date:  2004-05-24       Impact factor: 5.157

9.  MAP kinase phosphatase activity sets the threshold for thymocyte positive selection.

Authors:  Matthew L Bettini; Gilbert J Kersh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-27       Impact factor: 11.205

10.  DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility.

Authors:  Marjorie Maillet; Nicole H Purcell; Michelle A Sargent; Allen J York; Orlando F Bueno; Jeffery D Molkentin
Journal:  J Biol Chem       Date:  2008-08-27       Impact factor: 5.157

View more
  80 in total

1.  Research Resource: A Reference Transcriptome for Constitutive Androstane Receptor and Pregnane X Receptor Xenobiotic Signaling.

Authors:  Scott A Ochsner; Anna Tsimelzon; Jianrong Dong; Cristian Coarfa; Neil J McKenna
Journal:  Mol Endocrinol       Date:  2016-07-13

2.  Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.

Authors:  Kai-Min Lin; Sue-Jane Lin; Juin-Han Lin; Pei-Yi Lin; Pu-Lin Teng; Hsueh-Erh Wu; Te-Huei Yeh; Ying-Piao Wang; Mei-Ru Chen; Ching-Hwa Tsai
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

3.  EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells.

Authors:  Shaorong Yu; Huanhuan Sha; Xiaobing Qin; Yan Chen; Xiaoyou Li; Meiqi Shi; Jifeng Feng
Journal:  Oncogene       Date:  2020-01-30       Impact factor: 9.867

4.  Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.

Authors:  C Vanesa Díaz-García; Alba Agudo-López; Carlos Pérez; Elena Prieto-García; Lara Iglesias; Santiago Ponce; Analia Rodríguez Garzotto; José L Rodríguez-Peralto; Hernán Cortés-Funes; José A López-Martín; M Teresa Agulló-Ortuño
Journal:  Tumour Biol       Date:  2014-10-25

5.  PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Authors:  Haiying Cheng; Zhenfeng Zhang; Alain Borczuk; Charles A Powell; Adayabalam S Balajee; Howard B Lieberman; Balazs Halmos
Journal:  Carcinogenesis       Date:  2012-12-28       Impact factor: 4.944

6.  BRG1/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization.

Authors:  Tess Orvis; Austin Hepperla; Vonn Walter; Ian J Davis; Bernard Weissman; Shujie Song; Jeremy Simon; Joel Parker; Matthew D Wilkerson; Nisarg Desai; Michael B Major; D Neil Hayes
Journal:  Cancer Res       Date:  2014-08-12       Impact factor: 12.701

7.  RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Authors:  Haiying Cheng; Yiyu Zou; Jeffrey S Ross; Kai Wang; Xuewen Liu; Balazs Halmos; Siraj M Ali; Huijie Liu; Amit Verma; Cristina Montagna; Abraham Chachoua; Sanjay Goel; Edward L Schwartz; Changcheng Zhu; Jidong Shan; Yiting Yu; Kira Gritsman; Roman Yelensky; Doron Lipson; Geoff Otto; Matthew Hawryluk; Philip J Stephens; Vincent A Miller; Bilal Piperdi; Roman Perez-Soler
Journal:  Cancer Discov       Date:  2015-09-14       Impact factor: 39.397

8.  Cordycepin promotes apoptosis by modulating the ERK-JNK signaling pathway via DUSP5 in renal cancer cells.

Authors:  Jung-Hoo Hwang; Jong Cheon Joo; Dae Joon Kim; Eunbi Jo; Hwa-Seung Yoo; Kyung-Bok Lee; Soo Jung Park; Ik-Soon Jang
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

9.  Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.

Authors:  Bryant Harbourne; Min Hee Oh; William W Lockwood; Harold Varmus; Arun M Unni; Sophia Wild; John R Ferrarone
Journal:  Elife       Date:  2018-11-26       Impact factor: 8.140

10.  EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.

Authors:  Janyaporn Phuchareon; Frank McCormick; David W Eisele; Osamu Tetsu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.